Efficacy of multicomponent antihypertensive therapy in achieving blood pressure goal in patients with resistant hypertension
Background. The purpose was to assess the antihypertensive efficacy and influence on blood pressure (BP) daily profile of multicomponent antyhypertensive therapy in patients with resistant hypertension and high cardiovascular risk. Materials and methods. Twenty-three patients with resistant hypertension of II–III grade (ESH/ESC, 2011) were observed. Average age was 57.88 ± 10.03 years, and mean duration of hypertension was 8.65 ± 5.28 years. BP daily profile was evaluated with computer system. Results. Application of multicomponent antyhypertensive therapy in hypertensive patients with high and very high risk of cardiovascular complication allows achieve goal systolic BP and diastolic BP. The results of the treatment demonstrate normalization of disturbed BP profile, disturbed BP variability and index of BP load, positive dynamics of dipping status. Conclusions. Combined using of indapamidum with RAAS inhibitions + β bloker + spirolonolactone was found to have a high antihypertensive efficiency, to improve BP profile being metabolic neutrality, and to have a good tolerance, that qualifies this combination as the most optimal and effective for the reduction of cardiovascular complication in majority of patients.
Full Text:PDF (Русский)
ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension // J. Hypertension. — 2007. — Vol. 25. — Р. 1105-1187.
Resistant Hypertension: Diagnosis, Evaluation, and Treatment: AScientific Statement From the American Heart Association Professional Education Commit teeof the Council for High Blood Pressure Research / A.C. David, J. Daniel, T. Stephen // Hypertensionaha. — 2008, Apr. — P. 1403-1419.
Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research // Hypertension. — 2008. — Vol. 51. — P. 1403.
Acelajado M.C., Pisoni R., Dudenbostel T. et al. Refractory hypertension: definition, prevalence, and patient characteristics // J. Clin. Hypertens. (Greenwich). — 2012. — Vol. 14(1). — P. 7-12.
Cushman W.C., Ford C.E., Cutler J.A., Margolis K.L., Davis B.R., Grimm R.H., Black H.R., Hamilton B.P., Holland J., Nwachuku C., Papademetriou V., Probstfield J., Wright J.T., Alderman M.H., Weiss R.J., Piller L., Bettencourt J., Walsh S.M., for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Clin. Hypertens. — 2002. — 4. — P. 393-404.
Mancchia A., Zancetti A., Agapiti-Rosei E. et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy // Circulation. — 1997. — Vol. 95. — Р. 1464-70.
Laurent S., Cockcroft J., Van Bortel L. et al. on behalf of the European Network for Non-invasive Investigation of Large Arteries. Eхpert consensus document on arterial stiffness: methodological issues and clinical applications // Europ. Heart J. — 2006. — Vol. 27. — Р. 2588-2605.
Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research // Hypertension. — 2008. — 51. — P. 1403-1419.
Copyright (c) 2018 HYPERTENSION
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2018